| 38th week of 2011 patent applcation highlights part 38 |
| Patent application number | Title | Published |
|---|
| 20110229395 | PHOTOCATALYST COMPRISING TiO2 AND ACTIVATED CARBON MADE FROM DATE PITS - A photocatalyst is provided that comprises activated carbon produced from date pits, impregnated with TiO | 2011-09-22 |
| 20110229396 | CATALYST AND PROCESS - The invention concerns a process for the oxidation of organic compounds contained in a gas stream and comprises the step of introducing the gas stream containing the organic compounds together with sufficient oxygen to effect the desired amount of oxidation into an oxidation reactor containing an oxidation catalyst and maintaining the temperature of said gas stream at a temperature sufficient to effect oxidation, characterised in that the oxidation catalyst contains at least 0.01% by weight of ruthenium, cobalt or manganese. | 2011-09-22 |
| 20110229397 | PROCESS AND APPARATUS FOR CONTINUOUS FLOW SYNTHESIS OF NANOCRYSTALS - Novel reactor, systems and methods of preparing nanocrystals in a continuous flow-through process are provided. The novel reactor is highly configurable and can be modified to achieve desired reaction times of a flow through mixture. The reactor is designed to provide uniform, efficient heating of the reaction mixture. | 2011-09-22 |
| 20110229398 | FLUIDIZED BED REACTOR, THE USE THEREOF, AND A METHOD FOR THE ENERGY-INDEPENDENT HYDROGENATION OF CHLOROSILANES - The present invention relates to a device, to the use thereof, and to a method for the substantially energy-independent continuous production of chlorosilanes, particularly for the production of trichlorosilane as an intermediate product for yielding high-purity silicon. | 2011-09-22 |
| 20110229399 | Method for the production of polycrystalline silicon - The process for the production of polycrystalline silicon starting from metallurgical silicon, milled up to a predetermined granulometry, implies the reaction of metallurgical silicon with anhydrous hydrogen fluoride (HF), to obtain silicon tetrafluoride (SiF | 2011-09-22 |
| 20110229400 | PROCESS FOR PRODUCING HYDROGEN - A process is described for producing hydrogen comprising producing an aqueous feed stream comprising 5% to 15% wt. ethanol by a biomass fermentation process; and contacting the reformer feed stream with a hydrocarbon stream and a catalyst in a reformer under reforming conditions to produce a reformer product stream comprising hydrogen. | 2011-09-22 |
| 20110229401 | Carbon Films Produced from Ionic Liquid Carbon Precursors - The invention is directed to a method for producing a film of porous carbon, the method comprising carbonizing a film of an ionic liquid, wherein the ionic liquid has the general formula (X | 2011-09-22 |
| 20110229402 | CARBON NANOFIBERS AND PROCEDURE FOR OBTAINING SAID NANOFIBERS - The object of the present invention is carbon nanofibers mainly characterized by their high specific volume of mesopores, their high gas adsorption capacity and presenting a graphitic hollow structure. A second object of this invention is a procedure for obtaining such carbon nanofibers, which makes use of a metallic nickel catalyst and specific process furnace parameters that combined with the chemical composition of the furnace atmosphere and the fluidodynamic conditions of the gas stream inside the furnace, result in a faster growth of the carbon nanofibers and also in a higher quality of the carbon nanofibers obtained. | 2011-09-22 |
| 20110229403 | Gaseous Ammonia Removal System - A system and method for passive capture of ammonia in an enclosure containing material that gives off ammonia. The invention allows for the passage of gaseous NH | 2011-09-22 |
| 20110229404 | PROCESS FOR PRODUCING HYDROGEN - A process is described for producing hydrogen comprising producing an aqueous feed stream comprising 5% to 15% wt. ethanol by a biomass fermentation process; separating at least a portion of the water from the feed stream so that the concentration of ethanol in the resulting reformer feed stream is in the range of from 15% to 35% wt.; and contacting the reformer feed stream with a catalyst in a reformer under reforming conditions to produce a reformer product stream comprising hydrogen wherein the pressure in the reformer is in a range of from 100 psi to 600 psi. | 2011-09-22 |
| 20110229405 | PROCESS FOR PRODUCING HYDROGEN - A process is described for producing hydrogen comprising producing an aqueous feed stream comprising 5% to 15% wt. ethanol by a biomass fermentation process; separating at least a portion of the water from the feed stream so that the concentration of ethanol in the resulting reformer feed stream is in the range of from 15% to 35% wt.; and contacting the reformer feed stream with a catalyst in a reformer under steam reforming conditions to produce a reformer product stream comprising hydrogen wherein substantially no oxygen is added to the reformer. | 2011-09-22 |
| 20110229406 | Material and methods for treating or preventing HER-3 associated diseases - Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example. | 2011-09-22 |
| 20110229407 | Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof - The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of hepatocellular carcinoma, hepatoblastoma, germ cell tumors carcinoma and other AFP-producing tumors. | 2011-09-22 |
| 20110229408 | SODIUM-IODIDE SYMPORTER GENE REPRESSOR BINDING SITE - The present disclosure relates to a sodium iodide symporter (NIS)-repressor binding sites (NRBS) consensus sequence consisting of a DNA molecule having the sequence 5′-T/C(G/A)GCCT(T/C)A(G/A)TTTCCCCA(T/C)CTGT-3′(the “consensus NRBS”). The disclosure further relates to methods of restoring iodide transport in dedifferentiated thyroid cancer cells by interfering with formation or function of the NIS repressor. | 2011-09-22 |
| 20110229409 | LINKABLE LEWIS X ANALOGS - Disclosed herein is a class of linkable tetrasaccharide compounds that includes the amino phenyl glycoside of sialyl Lewis X (SLe | 2011-09-22 |
| 20110229410 | TECHNETIUM-DIPYRIDINE COMPLEXES, AND METHODS OF USE THEREOF - One aspect of the invention relates to novel complexes of technetium (Tc) with various heteroaromatic ligands, e.g., pyridyl and imidazolyl ligands, and their use in radiopharmaceuticals for a variety of clinical diagnostic and therapeutic applications. Another aspect of the invention relates to novel pyridyl ligands that form a portion of the aforementioned complexes. Methods for the preparation of the technetium complexes are also described. Another aspect of the invention relates to novel pyridyl ligands based on derivatized lysine, alanine and bis-amino acids for conjugation to small peptides by solid phase synthetic methods. Additionally, the invention relates to methods for imaging regions of a mammal using the complexes of the invention. | 2011-09-22 |
| 20110229411 | USE OF P2X7 PATHWAY FOR ASSESSING THE SENSITIVITY OF A SUBJECT TO A CANCER TREATMENT - The present invention concerns methods for assessing the sensibility of a subject to an anticancer treatment, for screening compounds which are useful for treating a cancer and for determining the likelihood of a metastatic relapse in a subject. The methods are based on the finding that a non-functional P2X7-elicited NALP3 inflammasome pathway in a subject is indicative of a resistance to treatment. The invention further concerns methods for treating a cancer and for restoring the sensitivity of the subject to a cancer treatment. | 2011-09-22 |
| 20110229412 | ANIMAL MODEL OF CENTRAL NEUROPATHIC PAIN AND MEHTODS OF MAKING AND USING THE SAME - The present disclosure describes an animal model of central neuropathic pain relevant to spinal cord injury, as well as methods of using the model to screen for therapeutic agents and to test existing therapies. | 2011-09-22 |
| 20110229413 | TREATMENT OF AMYLOIDOGENIC DISEASES - The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to Aβ. The invention also provides monitoring regimes that as can assess changes in symptoms or signs of the patient following treatment. | 2011-09-22 |
| 20110229414 | Contrast Agents For Detecting Protease Activity By Means Of Hyperpolarization And For Stratifying Patients - A contrast agent is disclosed for imaging methods. In at least one embodiment the contrast agent includes a construct including i) at least two copies of a substrate for at least one tumor-specific protease, and ii) at least one linker having at least one recognition site for at least one tumor-specific protease, wherein a hyperpolarization site is located at the N and/or C terminus of the substrate, and wherein the linker is configured such that the hydrophobic ends of the substrate interact and form a central core by means of noncovalent interactions with the lipophilic residues, and the contrast agent together with a parahydrogen metal template for use in an imaging method for diagnosing a tumor. At least one embodiment of the invention further relates to a method for imaging a tumor tissue, wherein the above-described contrast agent accumulated in a tumor tissue is imaged using a suitable imaging method after hyperpolarization by way of contact with a parahydrogen metal template, and also to a method for imaging a tumor tissue in a patient, wherein a) a contrast agent as described above is administered to a patient, b) a parahydrogen metal template is administered to the patient, and c) the presence of a tumor is depicted using an imaging method. | 2011-09-22 |
| 20110229415 | SEMI-SYNTHETIC ANTIBODIES AS RECOGNITION ELEMENTS - The presently-disclosed subject matter is directed to biosensors for detecting molecules of interest, and systems and methods for using same. The biosensors include an antibody and a probe covalently-linked to the antibody. The antibody has an antigen-binding site that selectively binds the molecule of interest and a purine-binding site, which is at a location distinct from that of the antigen-binding site. The probe includes a purine molecule, which is covalently bound at the purine-binding site to the antibody, and a label linked to the purine molecule. Upon binding of the molecule of interest to the biosensor antigen-binding site, the biosensor undergoes a conformational change, which detectably alters a signal of the label such that the molecule of interest can be detected. | 2011-09-22 |
| 20110229416 | AMPHIPHILIC MACROMOLECULES FOR SOLUBILIZING NANOCRYSTALS - Certain embodiments of the invention provide amphiphilic macromolecules and nanocrystals encapsulated by amphiphilic macromolecules. Additionally, certain embodiments of the invention also provide nanocrystals that are water-solubilzed using functionalized AMs capable of coordinating to the nanocrystal surface. | 2011-09-22 |
| 20110229417 | Emollient Foams for Treatment of Seborrheic Dermatitis - Described herein are emulsions and compositions for the treatment of various dermatoses. The emulsions may be formulated as aerosol compositions. The aerosol propellant may be a hydrofluoroalkane propellant. Also described are methods of treating dermatoses, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition. The dermatosis may be seborrheic dermatitis. | 2011-09-22 |
| 20110229418 | Compositions and Methods of Treating and Preventing Lung Cancer - Compositions and methods for treating and preventing cancer, particularly lung cancer, are provided. | 2011-09-22 |
| 20110229419 | CANKER SORE PREVENTION AND HEALING - A product for preventing and healing canker sores may comprise a mouth product; a Dead Sea salt; and sodium chloride mixture. The Dead Sea salt and the sodium chloride mixture may be mixed with the mouth product. The Dead Sea salt and sodium chloride mixture may act to prevent and heal the canker sores. | 2011-09-22 |
| 20110229420 | Cleaning Composition Containing Substituted Starch - A cleaning composition having from 0.05% to 30% by weight of surfactant and from 0.01% to 10% by weight of substituted starch, wherein the substituted starch has:
| 2011-09-22 |
| 20110229421 | SURFACE-TREATED CALCIUM PHOSPHATE PARTICLES SUITABLE FOR ORAL CARE AND DENTAL COMPOSITIONS - Calcium phosphate particles are described comprising a surface treatment wherein the surface treatment comprises at least one sugar alcohol, at least one glycerophosphoric acid compound, or mixture thereof. Also described are various oral care compositions comprising surface treated calcium phosphate particles and methods of surface treating calcium phosphate particles. | 2011-09-22 |
| 20110229422 | Tooth Whitening Compositions and Methods - A non-cytotoxic chlorine dioxide composition and a mixed agent bleaching composition for tooth whitening are disclosed. Methods of use are also provided. | 2011-09-22 |
| 20110229423 | PACAP SIGNALING PATHWAY MODULATORS FOR TREATING INFLAMMATORY SKIN DISEASES HAVING A NEUROGENIC COMPONENT, NOTABLY ROSACEA, AND COMPOSITIONS COMPRISED THEREOF - Modulators of specific PACAP receptors are useful for treating inflammatory skin diseases having a neurogenic component, and more particularly rosacea and/or facial erythema, compositions containing these and screening methods are described for identifying PACAP signaling pathway modulators. | 2011-09-22 |
| 20110229424 | FORMULA FOR REMOVING COLOR COATS AND VARIOUS SOIL LAYERS FROM SURFACES, METHOD FOR PRODUCING THE AGENT, AND METHOD FOR CLEANING - The invention relates to a cleaning agent, characterized in that the cleaning agent comprises a microemulsion or a fluid nanophase system, and has the following components: a) at least one non-water-soluble substance having a solubility in water of less than 4 g per liter; b) at least one amphiphile substance, NP-MCA, that has no tenside structure, does not form structures on its own, has a solubility in water or oil between 4 g and 1000 g per liter, and preferably does not accumulate at the oil-water boundary, with the provision that NP-MCA is not selected from among 2-Ethyl-1,3-Hexanediol, 2-Methyl-2,4-Pentanediol, 2-(n-Butyl)-2-Ethyl-1,3-Propanediol and/or 1,2-Diols; c) at least one anionic, cationic, amphoteric and/or non-ionic tenside; d) water and/or a water-soluble solvent having hydroxyl functionality and, optionally, additives. | 2011-09-22 |
| 20110229425 | HAIR COSMETIC COMPOSITION - A hair cosmetic composition used for dyeing, bleaching, or destaining hair contains amino-modified silicone, dimethicone, and polyethylene glycol having a number average molecular weight of 10,000 or more. | 2011-09-22 |
| 20110229426 | PERFUMING INGREDIENTS OF THE FLORAL AND/OR ANIS TYPE - The present invention concerns the use as perfuming ingredient, for instance to impart odor notes of the floral and/or green type, of a compound of formula 5 wherein R is an ortho, meta or para substituent of the phenyl, and represents a hydrogen atom or a C 1-2 alkyl or alkoxyl group; R 1 represents a hydrogen atom or a methyl or ethyl group; 10 R 2 represents a hydrogen atom or a C 1-3 alkyl group; and X represents a CHO, COOR 3, CH(OR 4) 2 or CN group, R 3 being a methyl or ethyl group, and R 4, taken seperately, being a methyl or ethyl group, or said R 4, taken together, a C 2-5 alkanediyl group; and at least one of said R, R 1 or R 2 represents a group containing at least one carbon atom. | 2011-09-22 |
| 20110229427 | Phosphoric Acid Esters Containing Phosphorus Atoms Bridged By Polyol Units - The invention relates to phosphoric acid esters containing A) at least one structural unit derived from substances of constituent a), the substances of constituent a) being selected from orthophosphoric acid and at least one of the derivatives thereof; B) at least one structural unit derived from substances of constituent b), the substances of constituent b) being selected from at least one compound of formula (I) R | 2011-09-22 |
| 20110229428 | FABRIC SOFTENING COMPOSITIONS AND METHODS - The invention provides fabric conditioning compositions, which include as the conditioning agent, one or more quaternary ester ammonium salt compounds, which include a mixture of quaternary mono-, di- and tri-ester ammonium salt components, wherein the amount of quaternary diester ammonium salts is greater than about 40% by weight, and the amount of quaternary triester ammonium salts is less than about 20% by weight based on the total amount of quaternary ester ammonium salts. The composition contains a high level of quaternary diester ammonium salt content, and low level of quaternary triester ammonium salt content. | 2011-09-22 |
| 20110229429 | CLEANSING COMPOSITION - The present invention is related to an aqueous cleansing composition for skin and keratin fibres especially human hair with excellent conditioning effects on skin and hair. The present inventors have surprisingly found out that an aqueous cleansing composition based on at least one foaming surfactant and comprising further at least one di alkyl ether and at least one high molecular weight polyethylene glycol cleanses and condition hair and skin excellently. The object of the present invention is a cleansing composition for skin and hair comprising at least one surfactant selected from anionic, non-ionic and amphoteric ones, at least one di alkyl ether of the general structure | 2011-09-22 |
| 20110229430 | Cosmetic Compositions Containing Thiomers For Hair Color Retention - Cosmetic hair treatment compositions comprising thiolated polymers having in the range of from about 5% to about 50% reactive thiol groups are provided. Also provided is a method for extending the color retention of color-treated hair. | 2011-09-22 |
| 20110229431 | METHODS USEFUL IN STUDYING OR MODULATING SKIN OR HAIR PIGMENTATION, PLANT EXTRACTS FOR USE IN COMPOSITIONS AND COSMETIC CARE METHOD - The invention relates to methods useful in studying or modulating skin or hair pigmentation and to the use of plant extracts in compositions as well as to methods comprising the topical use of such compositions to reduce or to enhance skin or hair pigmentation. | 2011-09-22 |
| 20110229432 | THERMOSENSITIVE COMPOSITION PREVENTING TISSUE ADHESION AND PREPARATION METHOD THEREOF - Provided is a thermosensitive composition preventing tissue adhesion and a method for preparing the same, and, more particularly, a thermosensitive composition preventing tissue adhesion which further contains a drug selectively inhibiting inflammatory response and a method for preparing the composition, in which the composition is produced through a chemical reaction by adding a cross-linking agent to an aqueous solution which contains a block copolymer containing a polyethyleneoxide block having the ability to suppress tissue adhesion, and a polymer with 10,000 to 1,000,000 g/mol of molecular weight which can be mixed with the copolymer; the composition is characterized in that the difference of viscosity, absorbance of visible rays region, and stability between the upper and lower liquid layers are within 10% when centrifuging the composition; and also the method for preparing the composition enhances cross-linking homogenization and viscosity stability through simultaneous spraying and stirring methods without a reaction retardant. | 2011-09-22 |
| 20110229433 | USE OF MODIFIED INTERLEUKIN-8 PROTEINS FOR TREATING REPERFUSION INJURY OR TRANSPLANT REJECTION - The present invention relates to the use of a modified interleukin 8 (IL-8) having increased GAG binding affinity and further inhibited or down-regulated biological activity compared to the respective wild type IL-8 for preparing a medicament for the prevention and/or treatment of ischemia reperfusion injury and/or transplant rejection in patients. | 2011-09-22 |
| 20110229434 | USES OF MAMMALIAN CYTOKINE; RELATED REAGENTS - Provided are methods of modulating dendritic cell activity using agonists or antagonists of a mammalian cytokine. Also provided are methods of treating immune disorders. | 2011-09-22 |
| 20110229435 | EXPRESSION AND PURIFICATION OF HIP/PAP AND USES THEREFOR - The present invention relates to methods of compositions comprising RegIII and HIP/PAP proteins, including the use of such proteins as diagnostic and therapeutic targets. | 2011-09-22 |
| 20110229436 | METHODS FOR REDUCING THE LIKELIHOOD OF SPONTANEOUS ABORTION DURING ASSISTED REPRODUCTION IN A SUBJECT - Compositions, kits and methods for the prevention of, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure during assisted reproduction are provided. The compositions, kits and methods provide an effective amount of granulocyte colony stimulating factor to prevent, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure of an embryo. | 2011-09-22 |
| 20110229437 | Method of Treating Asthma with Antiviral Agents - The present invention provides a method of treating asthma by administering a therapeutically effective amount of an antiviral agent to a patient. The antiviral agent may be a neuraminidase inhibitor, a viral fusion inhibitor, a protease inhibitor, a DNA polymerase inhibitor, a signal transduction inhibitor, a nucleoside reverse transcriptase inhibitor (NRTI), a non-nucleoside reverse transcriptase inhibitor (NNRTI) or an interferon. The antiviral agent may be administered to the patient by inhalation, nasally, intravenously, orally, subcutaneously, intramuscularly or transdermally. For example, the antiviral agent may be formulated for delivery as aerosols to the patient. | 2011-09-22 |
| 20110229438 | METHOD OF INHIBITING HEPATITUS C VIRUS BY COMBINATION OF A 5,6-DIHYDRO-1H-PYRIDIN-2-ONE AND ONE OR MORE ADDITIONAL ANTIVIRAL COMPOUNDS - The invention is directed to a method of treating infections by hepatitis C virus by administering N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.0 | 2011-09-22 |
| 20110229439 | COMPLEMENT PROTEINS - The present invention relates to classical pathway complement proteins and their use in the prognosis and prevention of diseases involving cone photoreceptor degeneration. Specifically, the present invention is directed to the use of one or more classical pathway complement proteins, preferably involved in the recognition phase, in the maintenance of cone photoreceptor cell viability in a degenerating retina. The invention is also directed to a method for determining the susceptibility, risk of development and/or progression of diseases involving cone photoreceptor degeneration in a subject. | 2011-09-22 |
| 20110229440 | Differentiation of Human Embryonic and Induced Pluripotent Stem Cells - The invention relates to culture systems, methods, and conditions that allow pluripotent undifferentiated hESCs or iPSCs to progressively and uniformly differentiate into cells of the chondrogenic lineage. | 2011-09-22 |
| 20110229441 | Method and Medium for Neural Differentiation of Pluripotent Cells - The invention relates to a culture medium comprising an inhibitor of the BMP signaling pathway; and an inhibitor of the TGF/activin/nodal signaling pathway and to a method for obtaining a population of neural precursors using said culture medium. | 2011-09-22 |
| 20110229442 | Cells exhibiting neuronal progenitor cell characteristics and methods of making them - Disclosed are cells exhibiting neuronal progenitor cell characteristics, and methods of making them from marrow adherent stem cells by regulating cellular pathways in the marrow adherent stem cells that are associated with glial transdifferentiation of the marrow adherent stem cells. | 2011-09-22 |
| 20110229443 | Composition for Cancer Prevention or Treatment Containing as Active Ingredient Plant Stem Cell Line Dervied from Cambium of Panax Ginseng Including Wild Ginseng or Ginseng - The present invention relates to a composition for preventing or treating cancer, which contains, as an active ingredient, a | 2011-09-22 |
| 20110229444 | Neuregulin And Cardiac Stem Cells - The present invention relates to compositions and methods for inducing cardiomyogenesis in mammalian cells, particularly embryonic stem cells in vitro and in vivo. | 2011-09-22 |
| 20110229445 | METHOD FOR HEALING BONE FRACTURE USING TRANSFECTED CHONDROCYTES - The application discloses a method for making bone at a bone defect site for a person suffering from low bone mass which includes inserting a gene encoding a protein having bone regenerating function into a connective tissue cell operably linked to a promoter, and transplanting the mammalian cell into the bone defect site, and allowing the bone defect site to make the bone. | 2011-09-22 |
| 20110229446 | Method and composition to relieve sexual discomfort and improve vaginal health - A method to reduce sexual discomfort for a woman during sexual intercourse vaginally introduces a lubricant composition comprising carrageenan comprising 0 to 92% by weight iota carrageenan, 10% to 100% by weight lambda carrageenan, and, 0 to 18% by weight kappa carrageenan; water such that the ratio of carrageenan to water is in the range of 1:10 to 1:50; at least one prebiotic; and, a natural humectant with a peak tackiness force of less than 50 g and a work of adhesion of less than 0.500 GS. | 2011-09-22 |
| 20110229447 | NUTRITIONAL SUPPORT TO PREVENT OR MODERATE BONE MARROW PARALYSIS OR NEUTROPENIA DURING ANTI-CANCER TREATMENT - The present invention relates to methods and immunonutritional compositions for preventing the impairment of the immune function during anti-cancer therapy, thereby attaining a better efficacy of the treatment. More particularly, the present invention relates to methods and immunonutritional compositions that can transiently preventing or moderating, bone marrow paralysis or neutropenia of a subject undergoing anti-cancer therapy-induced apoptosis or necrosis or other cell damage such that the innate and adaptive immune functions and normal physiology of the bone marrow are preserved, at least in part, which, in turn, lead to (i) a better tolerance and increased efficacy to anti-cancer therapy; (ii) transient augmentation or enhancement of immunocompetence of the immune cell; and (iii) optimization of the effects of and increase of immunocompetence of the immune cell weakened by anti-cancer therapy. | 2011-09-22 |
| 20110229448 | METHOD FOR IDENTIFYING ANTIGEN-SPECIFIC REGULATORY T CELLS - A method of identifying an antigen-specific regulatory T cell (Treg) from a subject is discussed wherein the method comprises quantitatively or qualitatively detecting co-expression of each of cell markers CD4, CD25 and CD134, or alternatively, N each of cell markers CD8, CD25 and CD137, as well as one or more cell markers selected from the group of Treg cell markers consisting of CD39, CD73, CD127, CTLA-4 and Foxp3 on a cell in a suitable lymphocyte-containing sample from the subject in response to exposure to a target antigen. Also discussed are methods of isolating and expanding the identified antigen-specific Treg population, which may permit antigen-specific Treg cell therapy. | 2011-09-22 |
| 20110229449 | PROPHYLAXIS AND TREATMENT OF MACULAR DEGENERATION AND RETINOPATHY USING A PRDX PROTEIN - The present invention provides an agent for the prophylaxis or treatment of retinopathy or AMD containing PRDX 5 or PRDX 6, as well as an agent for the prophylaxis or treatment of retinopathy or AMD containing a polynucleotide encoding PRDX 5 or PRDX 6. The present invention also provides a method for the prophylaxis or treatment of retinopathy or AMD in a patient suffering from the disease, which includes administering to the patient an effective amount of PRDX 5 or PRDX 6, or administering to the patient an effective amount of a polynucleotide encoding PRDX 5 or PRDX 6. | 2011-09-22 |
| 20110229450 | ENZYMES AND METHODS FOR DEGRADING S-TRIAZINES AND DIAZINES - The present invention relates to polypeptides for degrading s-triazines such as atrazine, as well as diazines. Also provided are polynucleotides encoding these polypeptides. The present invention also relates to the use of these polynucleotides and polypeptides in the bioremediation of s-triazines and diazines. | 2011-09-22 |
| 20110229451 | TEMPERATURE SENSITIVE MUTANTS OF MATRIX METALLOPROTEASES AND USES THEREOF - Provided are modified matrix metalloprotease (MMP) enzymes that exhibit temperature-dependent activity and uses thereof. The MMPs can be used, for example, to treat ECM-mediated diseases or disorders characterized by increased deposition or accumulation of one or more ECM components. | 2011-09-22 |
| 20110229452 | Ophthalmic Surgical Irrigating Solutions Containing Hyaluronidase - An ophthalmic irrigating solution containing hyaluronidase and an antioxidant is provided. The solution prevents a post-operative intraocular pressure rise when used during an ophthalmic surgical procedure, and also protects corneal endothelial cells. A method for preventing post-operative intraocular pressure increases in an eye during ophthalmic surgery involves irrigating an anterior chamber of the eye with an ophthalmic solution containing hyaluronidase and an antioxidant. Kits containing hyaluronidase and base medium solutions are also provided. The kits are designed such that the hyaluronidase and base medium solution are combined and administered together to an eye of a patient during or following an ophthalmic surgical procedure, such as cataract surgery, intraocular lens surgery, corneal transplant surgery, or glaucoma surgery. Administration of the components of the kit prevents an increase in post-operative intraocular pressure and also protects corneal endothelial cells. | 2011-09-22 |
| 20110229453 | BLOOD COAGULATION FACTOR INHIBITORS - The invention relates to novel compounds with formula (I) useful as blood coagulation factor inhibitors. The compounds (I) may be used for treatment of thrombotic conditions or as stabilizers of liquid formulations of blood coagulation factors, in particular liquid formulations of FVIIa, Factor VII variants, or Factor VII derivatives. | 2011-09-22 |
| 20110229454 | Use of Prourokinase and Variants Thereof in Facilitated Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction - In the field of biological medicines, a use of prourokinase (proUK) and variants thereof in facilitated percutaneous coronary intervention (PCI) in patients with acute myocardial infarction is provided. The use includes: within 6 hrs after a patient is afflicted with accurate myocardial infarction (AMI), firstly, performing thrombolytic therapy with proUK or variants thereof, and then, performing a PCI operation, to dredge the infarction related artery (IRA) as soon as possible, and re-establish an effective forward blood flow, such that an ischemic myocardium is reperfused. According to the present invention, the facilitated PCI for treatment of AMI with the proUK or variants thereof has an effect superior to that of direct PCI. | 2011-09-22 |
| 20110229455 | STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS - The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions. | 2011-09-22 |
| 20110229456 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY OPTIMAL PRESENTATION OF 5' ENDS - The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3′ ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5′ end. | 2011-09-22 |
| 20110229457 | INJECTABLE DRUG DELIVERY SYSTEM - The invention provides a formulation that includes a biocompatible solvent system, a biodegradable polymer that is substantially soluble in the biocompatible solvent system, and an active pharmaceutical ingredient that is substantially insoluble in the biocompatible solvent system. The formulation can form a drug-eluting implant, when injected into mammalian tissue. The solvent system and the biodegradable polymer can be selected so that the implant provides extended, delayed, controlled and/or modified release of the active pharmaceutical ingredient, for example, over the course of days, weeks or months. | 2011-09-22 |
| 20110229458 | METHODS FOR SELECTING PROTEASE RESISTANT POLYPEPTIDES - The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans. | 2011-09-22 |
| 20110229459 | ANTI-NR10 ANTIBODY AND USE THEREOF - The present inventors successfully obtained anti-NR10 antibodies having an effective neutralizing activity against NR10. The anti-NR10 antibodies provided by the present invention are useful as, for example, pharmaceuticals for treating or preventing inflammatory diseases. | 2011-09-22 |
| 20110229460 | ANTI-CD137 ANTIBODY AS AN AGENT IN THE TREATMENT OF INFLAMMATORY CONDITIONS - The present invention relates to the treatment of inflammatory conditions including atherosclerosis and sepsis. In particular, the invention relates to treatment of these conditions using antibodies. | 2011-09-22 |
| 20110229461 | PD-1 Antibodies - A humanised agonistic antibody which binds human PD-1 comprising a heavy chain and a light chain wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3 and the variable domain of the light chain comprises the sequence given in SEQ ID NO:4 for CDR-L1, the sequence given in SEQ ID NO:5 for CDR-L2 and the sequence given in SEQ ID NO:7 for CDR-L3. The invention also extends to therapeutic uses of the antibody molecules, compositions and methods for producing said antibody molecules. | 2011-09-22 |
| 20110229462 | Hepatocyte Growth Factor (HGF) Binding Proteins - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 2011-09-22 |
| 20110229463 | RECOMBINANT ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY COMPOSITIONS - The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides the use of an antibody composition with two distinct non-overlapping binding specificities to human EGFR. The antibody composition is effecting in treating cancer following treatment with other anti-EGFR antibodies, whether the cancer shows progression during or following the prior treatment or not. The antibody composition can also be used for repeated treatment of recurrent tumours following first-line therapy with the antibody composition of the invention, as the composition does not lead to selection of resistant tumours. A further therapeutic use is the use of an antibody composition of the invention for treatment of cancer that is resistant to known anti-EGFR antibodies. | 2011-09-22 |
| 20110229464 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION WITH MELATONIN ANALOGUES - Pharmaceutical compositions and methods for treating and/or preventing age-related macular degeneration with melatonin analogues are provided. | 2011-09-22 |
| 20110229465 | COMPOSITION FOR TREATING DISEASE - The present invention provides pharmaceutical compositions and kits comprising an agent capable of activating CD4+CD25+ regulatory T cells and methotrexate, and methods of treatment and medical uses utilising the same. | 2011-09-22 |
| 20110229466 | VASCULAR ENDOTHELIAL GROWTH FACTOR 2 - Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof. | 2011-09-22 |
| 20110229467 | TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER - The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject. | 2011-09-22 |
| 20110229468 | TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER - The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject. | 2011-09-22 |
| 20110229469 | METHODS FOR THE TREATMENT OF CANCER - Methods for treating cancer with at least one HGF-Met inhibitor and at least one EGFR inhibitor are provided | 2011-09-22 |
| 20110229470 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASE SECONDARY TO MULTIPLE SCLEROSIS - The invention provides methods of diagnosing multiple sclerosis (MS) patients, including methods of identifying multiple sclerosis patients who are at increased risk of developing a secondary autoimmune disease following lymphocyte depletion, caused, e.g., by treatment with an anti-CD52 antibody. Also embraced are methods of selecting treatment regimens for MS patients, and reagents useful in the above methods. | 2011-09-22 |
| 20110229471 | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNF ALPHA THERAPY IN INFLAMMATORY BOWEL DISEASE - The present invention relates to methods of prognosing responsiveness to anti-TNFα therapy by determining the presence or absence of risk factors in the individual. In one embodiment, the risk factors are genetic markers, serological markers and/or clinical phenotypes associated with non-responsiveness to treatment with anti-TNFα therapy in an individual diagnosed with IBD. | 2011-09-22 |
| 20110229472 | Peptides and Related Compounds Having Thrombopoietic Activity - The present invention relates generally to novel peptides and related compounds that have thrombopoietic activity. The compounds of the invention may be used to increase production of platelets or platelet precursors (e.g. megakaryocytes) in a mammal. | 2011-09-22 |
| 20110229473 | METHODS FOR USING TACI-IMMUNOGLOBULIN FUSION PROTEINS - Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors. | 2011-09-22 |
| 20110229474 | MONITORING AND INHIBITING HUMAN IMMUNODEFICIENCY VIRUS INFECTION BY MODULATING HMGB1 DEPENDENT TRIGGERING OF HIV-1 REPLICATION AND PERSISTENCE - Compositions and methods for modulating human immunodeficiency virus (HIV) infection involving substances that inhibit the ability of high mobility box 1 (HMGB1) protein to interact with natural killer (NK) cells. Therapeutic compositions comprising antibodies and drugs, such as glycyrrhizin, which bind to HMGB1. Methods of detecting or monitoring HIV infection involving detection or quantitation of HMGB1 or antibodies specific for HMGB1 in a biological sample. | 2011-09-22 |
| 20110229475 | NOVEL COMPOUNDS - The present invention relates to an antibody which has multiple specificities. In particular the antibody of the present invention binds to (cross react with) human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78. | 2011-09-22 |
| 20110229476 | MONOSPECIFIC AND MULTISPECIFIC ANTIBODIES AND METHOD OF USE - This invention relates to monospecific and multispecific antibodies that may be utilized for the diagnosis and treatment of various diseases. In addition, these antibodies may be modified by protease cleavage. Protease control or regulation may be provided by a protease site located in, for example, a linker. These protease-regulated antibodies may also be utilized for the diagnosis and treatment of various diseases. | 2011-09-22 |
| 20110229477 | Methods for Treatment of HIV and Other Infections Using a T Cell or Viral Activator and Anti-Retroviral Combination Therapy - Disclosed is a method for treating infection with a pathogen. The method involves administration of (1) a substance which induces active pathogen replication in a cell latently infected with HIV and (2) an anti-pathogen drug. Also disclosed are methods for expanding CD4+ T cells from peripheral blood mononuclear cells isolated from human subjects in the presence of an antiretroviral drug and for treating HIV infection by infusing the expanded CD4+ cells into HIV-infected patients. | 2011-09-22 |
| 20110229478 | ERBB3 BASED METHODS AND COMPOSITIONS FOR TREATING NEOPLASMS - The present invention relates to compositions and methods for treating neoplasms in mammals, particularly humans. More particularly, the present invention provides for methods for preventing, treating or delaying neoplasm in a mammal using an ErbB-3 protein, a nucleic acid encoding an ErbB-3 protein or a functional fragment thereof. The present invention also provides for an isolated nucleic acids encoding an extracellular domain of the ErbB-3 protein, or a functional fragment thereof, substantially purified extracellular domain of the ErbB-3 protein, or a functional fragment thereof and antibodies that bind to an epitope in an extracellular domain of the ErbB-3 protein, or a functional fragment thereof. The present invention further provides for pharmaceutical compositions and/or vaccines comprising the extracellular domain of the ErbB-3 protein, or a functional fragment thereof, or nucleic acids encoding and antibodies binding to such extracellular domain or functional fragments thereof. | 2011-09-22 |
| 20110229479 | GENETIC ALTERATIONS IN ISOCITRATE DEHYDROGENASE AND OTHER GENES IN MALIGNANT GLIOMA - We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas. | 2011-09-22 |
| 20110229480 | PTA072 PROTEIN - The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of B-cell non-Hodgkin's lymphoma, breast cancer, colorectal cancer, kidney cancer, pancreatic cancer or prostate cancer, for monitoring the effectiveness of B-cell non-Hodgkin's lymphoma, breast cancer, colorectal cancer, kidney cancer, pancreatic cancer or prostate cancer treatment, and for drug development. | 2011-09-22 |
| 20110229481 | CANCER-ASSOCIATED ANTIGEN ANALOGUE PEPTIDES AND USES THEREOF - First, to solve the problems of the present invention, the present inventors confirmed the presence of ovarian cancer antigen-specific T cells in the peripheral blood of ovarian cancer patients by using an experimental system that detects combinations of CD4 and IL-4 or IFNγ. Next, using analogue peptides of the core protein MUC16 of the ovarian cancer-associated antibody C125, the present inventors revealed that antigen-specific CD4-positive T cells are present at an average frequency of about 4% in the peripheral mononuclear cells of patients and healthy subjects. Then, the present inventors analyzed the epitope for T cells in the core protein MUC16 of the ovarian cancer-associated antigen CA125, and determined the amino acid sequence FTLNFTITN (SEQ ID NO: 1) to be a shorter epitope. The present inventors further discovered that the analogue peptide OVCA11: GHTAPOPLLVPFTLNFTITN (SEQ ID NO: 11) is suitable for T cell activation. | 2011-09-22 |
| 20110229482 | Method of inhibiting infection by HCV, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood by preventing viral entry into a cell - A method of inhibiting infection by Flaviviridae viruses including HCV, GBC/HGV, and BVD in addition to VSV and any other virus capable of forming a complex with a lipoprotein strategies: preventing formation of a complex should one form, altering the conformation of such a complex to prevent its interaction with the cell receptor, blocking the cell receptor for the complex using an antibody to the receptor, blocking binding of the lipoprotein complex to the cell receptor using soluble lipoprotein receptor or fragments thereof, or downregulating the LDL receptor activity of the cells. | 2011-09-22 |
| 20110229483 | TUMOR ANGIOGENESIS ASSOCIATED GENES AND A METHOD FOR THEIR IDENTIFICATION - Crucial to designing anti-angiogenic and vascular targeting approaches is the identification of specific target molecules. We compared transcriptional profiles of tumor endothelial cells with that of normal resting endothelial cells, normal but angiogenically activated placental endothelial cells, and cultured endothelial cells. Although the majority of transcripts were classified as general angiogenesis markers, we identified 17 genes that show specific overexpression in tumor endothelium. Antibody targeting of four cell-surface expressed or secreted products (vimentin, CD59, HMGB1 and IGFBP7) inhibited angiogenesis in vitro and in vivo. Finally, targeting endothelial vimentin in a mouse tumor model significantly inhibited tumor growth and reduced microvessel density. Our results demonstrate the utility of the identification and subsequent targeting of specific tumor endothelial markers for anticancer therapy. | 2011-09-22 |
| 20110229484 | Host Cell Kinases as Targets for Antiviral Therapies Against HCV Infection - The present invention provides several networks of cellular protein kinases as potential targets for medical intervention against hepatitis C virus (HCV) infection and HCV-related diseases and disorders in mammals, including humans. The invention relates to therapeutic protocols and pharmaceutical compositions designed to inhibit the activity of one or more of these protein kinases for the prevention and/or treatment of infections and diseases caused by HCV. The invention also relates to methods for the identification of kinase inhibitors that may be used to treat and/or prevent HCV infections and HCV-related diseases. | 2011-09-22 |
| 20110229485 | INHIBITION OF THE NT-3:TRKC BOUND AND ITS APPLICATION TO THE TREATMENT OF CANCER SUCH AS NEUROBLASTOMA - The subject matter of the present disclosure relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compounds to interact with neurotrophin 3 (NT-3 or NT3), to the extracellular domain, or TrkC receptor and/or to inhibit the dimerization of the intracellular domain of the TrkC receptor expressed in tumor cells, particularly in neuroblastoma. The disclosure also relates to a method for predicting the presence of metastatic cancer or a bad prognosis cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of neurotrophin 3. The disclosure further comprises kits and compounds as a medicament for the treatment of neuroblastoma or cancer overexpressing neurotrophin 3 by the tumor cells. | 2011-09-22 |
| 20110229486 | Monoclonal Antibodies Against NKG2A - The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders. | 2011-09-22 |
| 20110229487 | THERAPEUTIC AGENT COMPRISING ANTIBODY CAPABLE OF SPECIFICALLY BINDING TO HUMAN HMGB-1 AS ACTIVE INGREDIENT - Previously, it was difficult to obtain high-affinity antibodies that specifically bind to HMGB-1 but not to HMGB-2. Under this circumstance, the present inventors successfully obtained antibodies that are more reactive to HMGB-1 than to HMGB-2 by using specific peptides as an antigen. The present inventors also demonstrated that the antibodies had a HMGB-1-neutralizing activity. The present inventors administered the antibodies to amyloidosis model animals, and as a result, successfully demonstrated that the antibodies produced a significant therapeutic effect. | 2011-09-22 |
| 20110229488 | PROGASTRIN AND LIVER PATHOLOGIES - Progastrin levels are determined to diagnose one or more liver pathologies. | 2011-09-22 |
| 20110229489 | Antibodies with pH Dependent Antigen Binding - The present invention relates to antibodies with pH dependent binding to its antigen such that the affinity for antigen binding at physiological pH (i.e., pH 7.4) is greater than at endosomal pH (i.e., pH 6.0 or 5.5). In other words, the K | 2011-09-22 |
| 20110229490 | Lyophilized Formulations of Engineered Anti-IL-23p19 Antibodies - The present invention provides lyophilized formulations of antibodies, such as antibodies that specifically bind to human interleukin-23 p19 (IL-23p19), or antigen binding fragments thereof. | 2011-09-22 |
| 20110229491 | MINICHROMOSOME MAINTENANCE COMPLEX INTERACTING PROTEIN INVOLVED IN CANCER - The present invention relates to a protein that is interacting with the minichromosome maintenance complex in eukaryotes. More specifically, the invention relates to the use of a protein, interacting with the minichromosome complex, and the gene encoding this protein in diagnosis, prognosis and treatment of cancer. | 2011-09-22 |
| 20110229492 | COMPOSITIONS AND METHODS FOR DIAGNOSING, TREATING, AND PREVENTING PROSTATE CONDITIONS - Disclosed are compositions and methods for diagnosing, preventing, and treating prostate cancer and prostate intraepithelial neoplasia (PIN). | 2011-09-22 |
| 20110229493 | NEUREGULIN ANTAGONISTS AND USE THEREOF IN TREATING CANCER - The invention provides neuregulin antagonists and methods of using the neuregulin antagonists in delaying the time to tumor recurrence or preventing resistance of cancer cells to treatment with a therapeutic agent. | 2011-09-22 |
| 20110229494 | TENEURIN AND CANCER - The present invention relates to a method for treating cancer, for instance brain tumors, in a subject by inhibiting a teneurin by administering to said subject a therapeutically effective amount of a modulator of said teneurin, for example a specific antibody or a siRNA. The present invention also encompasses methods of diagnosing cancer by measuring levels of teneurin. | 2011-09-22 |
